The efficacy and safety of degarelix: a 12‐month, comparative, randomized, open‐label, parallel‐group phase III study in patients with prostate cancer

Supporters

Support the authors with ResearchCoin

Tip RSC

Journal

BJU International

Topics

Medicine

Internal Medicine

Urology

Pulmonary And Respiratory Medicine

Endocrinology, Diabetes And Metabolism

Show all topics

DOI

10.1111/j.1464-410x.2008.08183.x